Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines

Study Identifier
AP-BTXC-12-001
CT.gov Identifier
NCT01814670
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Toxins
    • Study Drug
  • botulinum toxin Type A
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18 - 60 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * moderate or severe frown lines * facial laser treatment between 4 to 8 weeks prior to Day 1
    Exclusion Criteria:
    * previous use of botulinum toxin for any indication * diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis * microdermabrasion or superficial peels, permanent make-up to the brow and forehead area within the last 3 months * facial cosmetic procedures within the last 6 Months * treatment to forehead, brow, nose or midface areas with any filler within the last 12 months * use of a new topical skin care product within 1 month of the screening * any prior forehead or periorbital surgery or brow lift * deep dermal scarring, excessively thick sebaceous skin, and/ or loss of skin elasticity * any facial skin infection or unhealed skin lesion * pregnant or breast-feeding

    Protocol Summary

    A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.

    Study Locations

    Location
    Status
    Location
    Beijing, China
    Status
    Not applicable